Pharmaceutical intermediates
Empagliflozin Intermediates
8 pharmaceutical intermediates for Empagliflozin. Indication: Chronic Renal Insufficiency; Heart Failure; Type 2 Diabetes Mellitus.
About Empagliflozin
- Originator
- Boehringer Ingelheim International Gmbh
- Indication
- Chronic Renal Insufficiency; Heart Failure; Type 2 Diabetes Mellitus
- Approved Date
- 12/09/2016
- DS/DP
- 08/01/2028
Available intermediates
8 intermediates currently listed for Empagliflozin. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (5-Bromo-2-chlorophenyl)(4-fluorophenyl)methanone | 915095-85-1 | / | / |
| (5-Bromo-2-chlorophenyl)[4-[[(3S)-tetrahydro-3-furanylloxy]phenyllmethanone | 915095-84-0 | / | / |
| (S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydrofuran | 915095-94-2 | / | / |
| (S)-3-[4-[(5-Bromo-2-chlorophenyl)methyl]phenoxy]tetrahydrofuran | 915095-89-5 | / | / |
| (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl] -D-glucitol tetraacetate | 915095-99-7 | / | / |
| (S)-(+)-3-Hydroxytetrahydrofuran | 86087-23-2 | / | / |
| 4-((5-Bromo-2-chlorophenyl)methyl)phenol | 864070-18-8 | / | / |
| 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone | 32384-65-9 | / | / |
Building toward Empagliflozin?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →